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Abstract 
OBJECTIVES 20-30% of patients with metformin treated type 2 diabetes experience 
gastrointestinal side effects leading to premature discontinuation in 5-10% of the cases. 
Gastrointestinal intolerance may reflect localised high concentrations of metformin in the gut. 
We hypothesized that reduced transport of metformin via the plasma membrane monoamine 
transporter (PMAT) and organic cation transporter 1 (OCT1) could increase the risk of severe 
gastrointestinal side effects. 
RESEARCH DESIGN AND METHODS The study included 286 severe metformin intolerant 
and 1128 tolerant individuals from the IMI DIRECT consortium. We assessed the association 
of patient characteristics, concomitant medication and the burden of mutations in the SLC29A4 
and SLC22A1 genes on odds of intolerance.   
RESULTS Women (p < 0.001) and older people (p < 0.001) were more likely to develop 
metformin intolerance. Concomitant use of transporter inhibiting drugs increased the odds of 
intolerance (OR 1.72, p < 0.001). In an adjusted logistic regression model, the G allele at 
rs3889348 (SLC29A4) was associated with gastrointestinal intolerance (OR 1.34, p = 0.005). 
rs3889348 is the top cis-eQTL for SLC29A4 in gut tissue where carriers of the G allele had 
reduced expression. Homozygous carriers of the G allele treated with transporter inhibiting 
drugs had over three times higher odds of intolerance compared to carriers of no G allele and 
not treated with inhibiting drugs (OR 3.23, p < 0.001). Using a genetic risk score derived from 
rs3889348 and SLC22A1 variants, the odds of intolerance was more than twice in individuals 
who carry three or more risk alleles compared with those carrying none (OR 2.15, p = 0.01).   
Conclusions: These results suggest that intestinal metformin transporters and concomitant 
medications play an important role in gastrointestinal side effects of metformin.   
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Metformin therapy can cause gastrointestinal discomfort that negatively affects quality of life 
and adherence to prescribed medications. Gastrointestinal side effects usually manifest as 
nausea, vomiting, diarrhoea, flatulence, indigestion, bloating, abdominal discomfort and 
stomach ache. 20-30% of metformin treated subjects with type 2 diabetes experience 
gastrointestinal side effects leading to premature discontinuation in 5-10% of the cases (1, 2). 
This inhibits adherence to therapy and may lead to a change of treatment, depriving intolerant 
patients of effective diabetes therapy. Despite its clinical importance, the underlying 
pathophysiology of metformin intolerance is not yet clear. However multiple possible 
hypotheses have been proposed including high intestinal metformin concentration (3, 4), its 
effect on the gut microbiota (5), altered transportation of serotonin or direct serotonergic effects 
(6), and reduced ileal absorption of bile acid salts (7).   
 
Metformin is not metabolized and is excreted unchanged in the urine. At physiologic pH, it is 
hydrophilic due to the presence of a quaternary ammonium group that results in a net positive 
charge. Therefore, Metformin does not efficiently diffuse across the biological membranes and 
requires carrier-mediated transport. Multiple solute carrier transporters expressed in 
membranes of the enterocytes, hepatocytes and the kidney are reported to be involved in the 
absorption, distribution and elimination of metformin. Metformin requires the entire length of 
the small intestine to be absorbed (8): around 20% of the administered dose is absorbed in the 
duodenum and 60% in the jejunum and ileum. The remainder reaches the colon and remains 
unabsorbed. PMAT and OCT1 are reported to play the major role in the intestinal absorption 
of metformin (9). While PMAT is expressed in the apical (luminal) membrane of the 
enterocytes, intestinal localization of OCT1 is ambiguous (9-11). An association between 
reduced function alleles in SLC22A1 and concomitant use of OCT1 inhibiting drugs with 
metformin intolerance has been reported (12, 13). An interaction between OCT1 and Serotonin 
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Transporter (SERT) has also been shown to play an important role in the pathophysiology of 
metformin intolerance (13). 
 
Whilst PMAT shares extensive substrate and inhibitor overlap with OCTs (14), there are no 
studies investigating its role in metformin intolerance. Therefore, we hypothesized that reduced 
transport of metformin by major transporters of metformin, PMAT and/or OCT1, could 
increase intestinal metformin concentration and subsequently increase the risk of GI side 
effects. To address this, we used prescribing, biochemistry and clinical data from 286 
metformin intolerant and 1128 tolerant individuals from the IMI DIRECT (DIabetes REsearCh 
on patient straTification) consortium (15). Although OCT3 is expressed in the intestine, there 
are no common functional variants described, and therefore we do not include OCT3 in this 
analysis.  
 
Research Design and Methods 
Study population 
286 metformin intolerant (cases) and 1128 metformin tolerant (controls) subjects were 
identified from prescribing data in the IMI DIRECT consortium from participating centres 
across northern Europe (15). Each participant consented to participate in the study and ethical 
approval was obtained from the medical ethics committees of the respective centres.  
All metformin intolerant (cases) and metformin tolerant (controls) had: type 2 diabetes 
diagnosed clinically, a creatinine clearance ≥ 60 mL/min at metformin exposure, and were 
white Europeans aged between 18-90 years at recruitment. 
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Definition of metformin intolerance  
The metformin intolerance phenotype was defined in two ways:  firstly, individuals who 
switched to an alternative agent within 6 months of stopping metformin (including modified 
release metformin) after having had up to 1000 mg daily metformin for up to 6 weeks, who 
also reported gastrointestinal side effects on the metformin treatment as the reason for 
switching or where gastrointestinal side effects were clearly documented in the clinical record 
as a reason for transfer. In an alternative definition, intolerant individuals were defined as those 
who could not increase their metformin immediate release dose above 500 mg daily despite an 
HbA1c > 7% (53 mmol/mol) and who either reported gastrointestinal side effects on more than 
500 mg, or where gastrointestinal side effects were clearly documented in the clinical record 
as a reason for transfer.  
Where the patient was asked to recall side effects, the intolerant event was limited to be within 
the last 5 years; if side effects were documented from clinical records then there was no time 
limit. Participants who did not recall being on metformin or having side effects were excluded 
(unless clearly documented in clinical records).   
 
Definition of metformin tolerance 
Metformin tolerant individuals were defined as those treated with ≥ 2000 mg of metformin per 
day for more than a year (excluding modified release formulations of metformin) and report no 
side effects.  
 
Clinical covariates  
Weight, height and creatinine were defined as the closest measured values within 180 days 
prior to the index intolerance event (ITE) and BMI was calculated as weight in kg / (height in 
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m)2. The ITE was defined as the date when patients report gastrointestinal symptoms of 
metformin intolerance for cases, and for controls it is the date when patients start 2000 mg of 
metformin. Daily dose was the last dose during ITE for cases, and it was determined as the 
mean dose of prescriptions encashed during the first six months of metformin therapy for 
controls.  
 
Concomitant medications  
Gut metformin transporters have strong substrate and inhibitor overlap (16). Therefore, we 
identified medications prescribed together with metformin previously reported to inhibit the 
PMAT and/or OCTs, proteins that mediate transmembrane trafficking of their target molecules, 
and are required for metformin absorption in the gut. These drugs are selected based on their 
reported half-maximal inhibitory concentration (IC50) values. Accordingly the use of any of the 
following medications with metformin were investigated: tricyclic antidepressants (TCAs) (17, 
18), proton pump inhibitors (PPIs) (19), citalopram (18), verapamil (17, 18), diltiazem (18), 
doxazosin (17, 18), spironolactone (17, 18), clopidogrel (20), rosiglitazone (21), quinine (18), 
tramadol (18, 22), codeine (23), dysopyramide (24), quinidine (21), repaglinide (21), 
propafenone (17), ketoconazole (17), morphine (22, 23), tropisetron (25), ondasetrone (25), 
antipsychotic agents (17) and tyrosine kinase inhibitors (26). 
 
Genotyping 
DNA samples from participants were genotyped at the University of Oxford (UOXF) using the 
Illumina Human Core Exome chip v1.0 (HCE24 v1.0). Genotype calling was performed using 
the GenCall algorithm in the GenomeStudio software supplied by Illumina. Data were 
subjected to a series of standard quality control analyses in order to highlight poorly performing 
genetic markers and samples prior to imputation.  
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Samples were excluded for any of the following reasons: call rate less than 95%, heterozygosity 
greater than 4 standard deviations (SD) from the mean, high correlation to another sample (pi-
hat ≥ 0.2) or identified as ethnic outlier from constructed axes of genetic variation from 
principal components analysis implemented in the Genome-wide Complex Trait Analysis 
(GCTA) software (v1.24.7) (27) using the 1000 Genome as a reference. Further filtration was 
performed to remove: non-autosomal markers, duplicate markers (sharing the same positions), 
markers with minor allele frequency (MAF) <1%, Hardy–Weinberg equilibrium (HWE) p-
value < 0.0001 and call rate < 98%. Imputation to the 1000 Genomes Phase 3 CEU reference 
panel was performed with ShapeIt (v2.r790) (28) and Impute2 (v2.3.2) (29).  
 
Single nucleotide polymorphism selection  
As there are no functionally characterised common nonsynonymous SNPs in the SLC29A4 
gene, the tagging intronic SNPs, rs3889348 and rs2685753 (r2 = 0.57, D’ = 1) had been 
previously shown to be associated with trough steady state metformin concentration (30).  
Therefore, the rs3889348 G>A genotype, was extracted from existing genome-wide data. The 
frequency of the minor allele (A) of rs3889348 was 38%. Data for previously reported missense 
SLC22A1 variants (M420del (18.6%), R61C (7.1%), G401S (3.1%)) were also extracted from 
the genome-wide data. There was no deviation from HWE for any polymorphism (p > 0.05). 
 
Statistical methods 
Categorical data are presented as frequency (percentage) and continuous variables as mean ± 
SD if normally distributed or as median and inter quartile range (IQR) otherwise. Students t-
test and the Mann-Whitney U test were used to compare differences in quantitative variables 
distributed normally or not, respectively. Comparison of categorical variables between cases 
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and controls was done using X2 test. Logistic regression was used to estimate the association 
of independent variables with metformin intolerance. Multivariate logistic regression analyses 
of metformin intolerance were performed with all the covariates included using SNPTEST 
(version 2.5.2) (31). Association of the intronic rs3889348 G>A in SLC29A4 was explored 
assuming additive genetic model. SLC22A1 variants (M420del, R61C, G401S) were grouped 
together by summing up the number of risk alleles. Combined unweighted genetic risk score 
(GRS) was generated as 0, 1, or 2 according to the number of reduced-function alleles in each 
individual. The combined genotype was then added to the multivariate analyses assuming an 
additive model. A two-tailed p-value less than 0.025 was considered statistically significant. 
 
Expression quantitative trait locus (eQTL) analyses 
We investigated whether rs3889348 is a cis-QTL in the gut using eQTL datasets comprising a 
total of 246 colon transverse and 122 terminal ilium samples from the Genotype-Tissue 
expression (GTEx) data release V6 (32). Tissue procurement, gene expression analysis, 
genotyping and eQTL analysis have been described previously (32-34). 
 
Results 
Phenotypic differences between tolerant and intolerant subjects 
The characteristics of tolerant and intolerant subjects are presented in Table 1. Women (p < 
0.001) and older people at diagnosis or at ITE (p < 0.001) were more likely to be metformin 
intolerant. Compared to tolerant subjects, metformin intolerant individuals had lower weight 
(p < 0.001), lower creatinine clearance (p = 0.036) and were treated with a lower metformin 
dose (p < 0.001).  
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Concomitant medications and intolerance  
This analysis was performed on 237 metformin intolerant and 1128 tolerant subjects who had 
complete data on history of concomitant medications. Forty percent of metformin intolerant 
subjects were taking one or more cation transporter inhibitory drugs compared to 24% in 
tolerant subjects (p < 0.0001) (Table 1). In a logistic regression model adjusted for age, gender, 
weight and concomitant use of these drugs increased the odds of being intolerant by 70% (OR 
= 1.72 [1.26-2.32], p < 0.001) (Supplementary Table 1). When the individual drug or drug 
groups were explored, concomitant use of metformin with either PPIs, TCAs or codeine 
increased the odds of metformin intolerance significantly (Figure 1). The number of subjects 
who have been coprescribed metformin with transporter inhibiting drugs are shown in 
Supplementary Table 2. 
 
Genetic variation in the gut metformin transporters and metformin intolerance 
In a logistic regression model, carriers of the G allele had 1.39 [1.15-1.69, p < 0.001] times 
higher odds of being intolerant to metformin (unadjusted). When rs3889348 was added to a 
model adjusted for age, sex, weight and genetic substructure, the presence of the G allele was 
independently associated with metformin intolerance (OR = 1.34[1.09-1.65], p = 0.005) 
(Supplementary Table 1). No statistically significant difference in any of the baseline 
phenotypes by genotype was observed (Supplemental Table 3). In addition, no significant 
interaction between rs3889348, the use of metformin transporter inhibiting drugs and any of 
the other clinical variables (age, gender) was observed.  
We then grouped subjects based on the combination of SLC29A4 genotype and concomitant 
use of metformin transporter inhibiting drugs. Taking those with no risk allele and not treated 
with transporter inhibiting drugs as the reference group, carriers of one and two G alleles treated 
with transporter inhibiting drugs had more than two (2.44 [1.30-4.78]) and three (3.23 [1.71-
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6.39]) fold higher odds of intolerance, respectively, after adjusting for age, sex and weight 
(Supplementary Table 4). 
The association between SLC22A1 genotypes and metformin intolerance has been previously 
reported (12, 35). We carried out an analysis on the association between two reduced function 
(R61C, G401S) and one loss of function (M420del) SLC22A1 SNPs and metformin intolerance 
using a combined unweighted GRS. In a logistic regression model adjusted for age, sex, weight, 
genetic substructure and concomitant use of transporter inhibiting drugs, the SLC22A1 GRS 
was not statistically significantly associated with metformin intolerance (OR = 1.35 [0.84-
2.12], p = 0.21). 
A GRS was then generated from SLC29A4 and SLC22A1 variants by summing up the number 
of risk alleles for each individual. Compared to those with no risk allele, metformin treated 
subjects with type 2 diabetes having two risk alleles had nearly a two-fold (1.93[1.10-3.65]) 
increased odds of GI intolerance. Those who carry 3 or more risk alleles had more than twice 
(2.15[1.20-4.12]) the odds of intolerance (Figure 2). 
Sensitivity analysis  
There was a big difference in sample size between metformin intolerant and tolerant subjects. 
In addition, there were significant difference in age and gender between cases and controls. 
Therefore, we carried out a sensitivity analysis by comparing the intolerant group (n=237) with 
age and sex matched subgroup of tolerant subjects (n=711). The main findings from the larger 
metformin tolerant group were confirmed in this sensitivity analysis (Supplementary Table 5 
and 6).  
rs3889348 is associated with altered PMAT expression in the gut  
Given PMAT is one of the major metformin transporters in the gut, we explored the possibility 
that the intronic SNP, rs3889348 is a cis-eQTL in the intestine utilizing the publicly available 
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data set from the GTEx portal (Version V6p) (32). The G-allele of rs3889348 (associated with 
higher risk of intolerance) was significantly associated with lower expression of SLC29A4 in 
the terminal ileum of the small intestine (β = -0.42, p = 2.1×10-04) and the transverse colon (β 
= -0.45, p = 1.4×10-08) (Supplemental Figure 1). rs3889348 is the top cis-eQTL for SLC29A4 
in the transverse colon. 
Conclusions  
Intestinal absorption of metformin is modulated by the function of cation transporters 
expressed in the gut. An association between reduced function alleles in the SLC22A1, 
encoding organic cation transporter 1, and metformin related GI side effects has been 
previously reported (12, 13, 36). However, the data on intestinal localization of OCT1 is 
ambiguous; with mixed reports suggesting in the apical (10) and basolateral (11, 37) sides. In 
addition to OCT1, PMAT also contributes to the intestinal absorption of metformin. PMAT is 
abundantly expressed in the human intestine and it is concentrated on the tips of the mucosal 
epithelial layer (38). Carriers of the G allele at this locus (rs3889348) had significantly reduced 
expression of SLC29A4 in the gut (32). This could lead to higher luminal concentration of 
metformin. In this current study we demonstrated a significant association of the G allele of an 
intronic SNP, rs3889348, in SLC29A4 encoding PMAT, with higher odds of GI intolerance 
after metformin therapy. Each copy of the G allele was associated with 1.34 times higher odds 
of metformin intolerance.  We also show that those who carry two or more variants at either 
SLC29A4 or SLC22A1, were two-fold more likely to have GI intolerance. Given that PMAT is 
apically located, this finding suggests that intolerance is driven by increased luminal 
concentration of metformin, rather than increased enterocyte concentration and direct toxicity 
to the enterocytes.   
There are a number of putative mechanisms whereby increased luminal metformin may 
increase GI intolerance to metformin (outlined in Figure 3).  Firstly, a higher concentration of 
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metformin in the gut has been shown to inhibit uptake of histamine and serotonin leading to 
increased luminal concentration of these biogenic amines (13). Metformin is also shown to 
inhibit diamine oxidase (DAO), an enzyme that degrades histamine, at therapeutic doses (6). 
Biogenic amines play an important role in the GI pathophysiology. Elevated levels of serotonin 
and histamine in the GI tract cause GI symptoms such as nausea, vomiting and diarrhea (6, 39). 
Serotonin is produced mainly in the gut and stored in the enterochromaffin cells of the 
epithelium. Its release activates gut sensory neurons that will increase intestinal motility, 
secretion and sensation (39, 40). Increased colon motility and softening of stool consistency 
has also been observed in serotonin reuptake transporter (SERT) knock-out mice (39, 40). In 
addition, a recent study from the GoDARTS cohort showed association of a composite SERT 
genotype, 5-HTTLPR (5-hydroxy tryptamine (serotonin) transporter linked polymorphic 
region)/rs25531, with intolerance to metformin in subjects with type 2 diabetes (13).  In this 
study, carriers of the low-expressing SERT S* alleles had more than 30% increased odds of 
metformin intolerance (OR=1.31, 95% CI 1.02-1.67, p = 0.031). Histamine is a monogenic 
amine stored in the enterochromaffin-like cells within the gastric glands of the stomach. 
Binding of histamine to the H1, H2 and H4 receptors that are highly expressed in the gut, 
stimulate gastric acid secretion, increase intestinal motility and smooth muscle inflammation 
(6). 
In addition to the potential role of local concentrations of serotonin and histamine, increased 
luminal concentrations of metformin could also cause intolerance by other mechanisms that 
need to be explored. For example, intolerance could be mediated by a reduction in bile acid 
reabsorption in the ileum leading to elevated bile acid levels in the colon (41), which is known 
to cause GI disturbances (42). In addition, metformin affects composition and function of the 
gut microbiota favoring the growth of some species like Akkermansia (5, 43-46). Furthermore, 
increased levels of active and total GLP-1 levels in subjects with type 2 diabetes and without 
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type 2 diabetes treated with metformin (47) have also been reported and this might increase GI 
side effects (48) (Figure 3).  
In this study we observed increased risk of intolerance with older age, female sex, lower weight 
and lower creatinine levels. Concomitant use of metformin with the PPIs and TCAs also 
increase the risk of intolerance. These findings are largely consistent with the results of 
previous studies, providing further evidence for clinical practice (12, 35). The FDA Adverse 
Events Reporting System (AERS) suggested that women experience more adverse effects than 
men (49). Several factors can contribute to these differences. Gender based variability in 
intestinal expression of drug transporters may result in variability in gut drug concentrations. 
Women have also slower gastric emptying, altered bile composition and slower intestinal 
transit time than men (50). These factors could in turn affect the rate and/or extent of absorption 
of oral medications and hence local drug concentrations in the gut. For a better understanding 
of the basic mechanisms of sex differences in metformin intolerance, future studies should be 
designed with a primary focus on this topic. 
In summary, we have identified a variant that alters intestinal expression of the cation 
transporter PMAT (SLC29A4) that increases risk of metformin associated gastrointestinal 
intolerance, and that combined with the previously reported SLC22A1 variants, this genotype 
profile can increase odds of metformin intolerance over 2-folds.  The apical location of PMAT 
means that reduced expression will result in increased luminal metformin concentration, 
suggesting that metformin intolerance is caused by this increased luminal concentration rather 
than increased enterocyte concentration.  
A limitation of this study was the definition for metformin induced GI intolerance. Even though 
we examined patient reports and clinical records for GI intolerance as a reason for stopping 
metformin and switching to other medications, there could be other reasons for stopping 
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metformin such as comorbidities that might cause GI disturbance. In addition, initial 
conclusions drawn from this study need validation and replication in a well-powered 
independent studies. 
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Tables 
 Table 1. Baseline characteristics of metformin tolerant and intolerant subjects. 
Variable Metformin Tolerant   
(n = 1,128) 
Metformin Intolerant 
(n = 286) 
p 
Age at diabetes diagnosis 
(years) 
55.88 ± 9.44 58.62 ± 10.65 <0.0001 
Age at ITE (years) 60.73 ± 9.84 64.63 ± 9.91 <0.0001 
Males/female (male %) 696/432 (61.7%) 117/169 (40.9%) <0.0001 
Weight (kg) 94.57 ± 18.91 88.84 ± 17.75 <0.0001 
BMI (kg/m2) 32.11 ± 6.01 31.60 ± 5.95 0.19 
Creatinine (µmol/dL) 79.89 ± 16.09 78.41 ± 19.33 0.25 
Creatinine clearance (mL/min) 85.17 ± 19.36 82.23± 29.44 0.04 
Dose (mg)* at diagnosis 1500 (1000-2000) 1000 (500-1000) <0.0001 
Duration of diabetes (years) 4 .0 (1.7-7.0) 4.0 (2.0-9.0) 0.09 
Use of metformin transporter 
inhibiting drugs  
274 (24.29%) 95 (40.08%) <0.0001 
ITE: index intolerance event *Median (IQR). Dose was calculated as the last dose during ITE for cases, and it 
was determined as the mean dose of prescriptions encashed during the first six months of metformin therapy for 
controls.  
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Figure legends 
Figure 1. Association of individual intestinal metformin transporter inhibiting drugs with 
intolerance. 
Figure 2. Association of a genetic risk score derived from SLC29A4 (PMAT) and SLC22A1 
(OCT1) with metformin intolerance. OR: odds ratio; GRS: genetic risk score. Bars indicate 
standard errors around the mean.  
Figure 3. Possible mechanisms for metformin intolerance. A) Metformin is absorbed from the 
gut lumen via cation transporters such as PMAT, OCT1, SERT and OCT3. B) Increased level 
of metformin in the gut lumen is observed when metformin is taken with cation transporter 
inhibiting drugs such as PPIs, TCAs and Codeine. These drugs competitively inhibit metformin 
uptake by the cation transporters. Metformin is also shown to inhibit diamine oxide, an enzyme 
that metabolize biogenic amines. In addition, transport capacity of the cation transporters could 
be reduced in carriers of reduced function (420del, 61C, 401S in SLC22A1) or low expressing 
alleles (rs3889348_G in SLC29A4) and hence increased luminal metformin level. Increased 
level of metformin increases the level of biogenic amines, affect the gut microbiota and elevate 
bile acid levels. These may cause symptoms of gastrointestinal side effects. 
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Figures 
 
Figure 1 
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Supplemental Tables 
Supplemental Table 1. Logistic regression model of metformin intolerance. 
Variable  OR [CI] p 
Age at ITE (years) 1.04[1.03-1.06] 7.44×10-08 
Gender  2.31[1.72-3.10] 2.52×10-08 
Weight (kg) 1.00[0.99-1.00] 0.20 
Use of metformin 
transporter inhibiting drugs 
1.72[1.26-2.32] 5.17×10-04 
rs3889348  1.34[1.09-1.65] 0.005 
Gender coded as women vs men. ITE: index intolerance event  
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Supplementary Table 2. Number of patients treated concomitantly with metformin 
transporter inhibiting drugs in the intolerant and tolerant groups. 
 
Drug/ Drug Class  Intolerant group (237)  Tolerant group (1128)  p 
PPI 58 (24.5%) 156 (13.8%) <0.001 
Codeine 22 (9.3%) 35 (3.1%) <0.001 
TCA 17 (7.2%) 33 (2.93%) 0.003 
Tramadol 10 (4.2%) 18 (1.6%) 0.004 
Clopidogrel 5 (2.1%) 14 (1.24%) 0.46 
Spironolactone 3 (1.3%) 9 (0.8%) 0.75 
Verapamil 3 (1.3%) 8 (0.7%) 0.64 
Data are presented as numbers of patients (percentages). TCAs, tricyclic antidepressants; PPIs, proton pump 
inhibitors.  
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Supplemental Table 3. Population characteristics by rs3889348 genotype. 
 rs3889348 genotype  
AA (n = 205) GA (n = 681) GG (n = 532) p 
Age at ITE (years) 61.03 ± 10.50 61.34 ± 10.0 61.94 ± 9.73 0.21 
Age at diagnosis (years) 55.97 ± 10.32 56.31 ± 9.67 56.78 ± 9.65 0.27 
Gender (women %) 36.6% 42.6% 45.1%  0.11* 
Weight (kg) 97.21 ± 19.39 92.53 ± 18.22 93.15 ± 19.43 0.06 
BMI (kg/m2) 32.77 ± 6.02 31.89 ± 6.09 31.88 ± 5.96 0.15 
Height (m) 1.72 ± 0.10 1.71 ± 0.10 1.71 ± 0.10 0.29 
Creatinine (µmol/dL) 80.51 ± 15.57 79.09 ± 16.29 79.90 ± 17.80 0.95 
Creatinine clearance (mL/min) 84.75 ± 18.95 84.98 ± 18.55 84.04 ± 20.80 0.52 
HbA1c (%) 8.21 ± 1.59 8.18 ± 1.62 8.39 ± 1.75 0.11 
Diabetes duration (years)† 4 [1.16-7.00]  4 [2.00-7.19] 4 [1.78-7.00] 0.78‡ 
Dose (mg)†  1000 (1000-1500) 1000 (1000-1500)  1000 (1000-1500)  1.00‡ 
Drug naïve (%) 44.1% 51.7% 51.4%  0.14* 
Use of metformin transporter 
inhibiting drugs (%) 
 22.4%  27.6%  28.8%  0.27* 
*chi-square test for independence, ‡kruskal-Wallis one-way analysis of variance, †Median (IQR). ITE: index 
intolerance event  
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Supplemental Table 4. Joint effect of SLC29A4 (PMAT) genotype and metformin transporter 
inhibiting drugs on metformin intolerance. 
  Intolerant/Tolerant OR [95% CI] p 
Carries no risk allele and not treated with metformin 
transporter inhibiting drugs 
15/141 1 --- 
Carries one risk allele and not treated with metformin 
transporter inhibiting drugs  
67/408 1.52 [0.86-2.88] 0.17 
Carries two risk alleles and not treated with metformin 
transporter inhibiting drugs  
60/305 1.76 [1.01-3.35] 0.04 
Carries no risk allele and treated with metformin 
transporter inhibiting drugs  
8/37 1.74 [0.64-4.46] 0.25 
Carries one risk allele and treated with metformin 
transporter inhibiting drugs 
44/137 2.44 [1.30-4.78] 0.007 
Carries two risk alleles and treated with metformin 
transporter inhibiting drugs 
43/100 3.23 [1.71-6.39] < 0.001 
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Supplementary Table 5. Joint effects of PMAT genotype and metformin transporter inhibiting 
drugs on intolerance after matching subjects for age and gender.  
 
 OR (95% CI)  p 
Weight   0.99[0.98-1.00] 0.08 
Use of metformin transporter inhibiting drugs  1.75[1.28-2.38] <0.001 
rs3889348_G 1.26[1.02-1.59] 0.03 
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Supplemental Table 6. Joint effect of SLC29A4 (PMAT) genotype and metformin transporter 
inhibiting drugs on metformin intolerance after matching patients for age and gender. 237 cases 
and 711 controls (1 case ~3 controls). 
 
  Intolerant/T
olerant 
OR [95% CI] p 
Carries no risk allele and not treated with metformin 
transporter inhibiting drugs 
15/93 - - 
Carries no risk allele and treated with metformin 
transporter inhibiting drugs 
8/18 2.76[0.99-7.38] 0.05 
Carries one risk allele and not treated with metformin 
transporter inhibiting drugs 
67/234 1.78[0.99-3.37] 0.06 
Carries one risk allele and treated with metformin 
transporter inhibiting drugs 
60/189 1.97[1.09-3.76] 0.03 
Carries two risk allele and not treated with metformin 
transporter inhibiting drugs 
44/100 2.73[1.45-5.37] 0.003 
Carries two risk alleles and treated with metformin 
transporter inhibiting drugs 
43/77 3.46[1.82-6.88] <0.001 
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Supplemental Figures 
 
Supplemental Figure 1. Boxplot of association between rs3889348 genotype and SLC29A4 
(PMAT) expression in the gut, colon transverse (left side) and terminal ilium of the small 
intestine (right side). 
 
 
 
 
 
 
 
